Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer

Researchers at Mass General Brigham Cancer Institute demonstrated that pralsetinib, an FDA-approved targeted therapy, delivered durable responses in 281 patients with RET fusion-driven lung cancer. A 42-month follow-up study confirmed the treatment's